MAM
XLRN

Martingale Asset Management’s Acceleron Pharma XLRN Stock Holding History

Martingale Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-134,635
Closed -$23.2M – 921
2021
Q3 		$23.2M Sell
134,635
-25,713
-16% -$3.36M 0.3% 126
2021
Q2 		$20.1M Buy
160,348
+11,502
+8% +$1.45M 0.23% 146
2021
Q1 		$20.2M Buy
148,846
+42,095
+39% +$5.44M 0.23% 143
2020
Q4 		$13.7M Buy
106,751
+78,589
+279% +$9.21M 0.16% 156
2020
Q3 		$3.17M Buy
28,162
+3,651
+15% +$363K 0.04% 309
2020
Q2 		$2.34M Buy
24,511
+20,707
+544% +$2M 0.03% 477
2020
Q1 		$342K Buy
+3,804
New +$296K ﹤0.01% 871

Martingale Asset Management's XLRN Position: Q4 2021 in Review

Martingale Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 134,635 shares — an estimated $23.2M sold.

Martingale Asset Management first reported a position in XLRN in Q1 2020 and held it in 7 quarters. The position peaked at $23.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Martingale Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Martingale Asset Management sold 134,635 Acceleron Pharma shares in Q4 2021, an estimated $23.2M.
  • Martingale Asset Management first reported a position in Acceleron Pharma in Q1 2020 and held it in 7 quarters.
  • Martingale Asset Management's Acceleron Pharma position peaked at $23.2M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Martingale Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.